Cargando…

Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale

BACKGROUND: Although oxaliplatin is widely established as a standard treatment in colorectal cancer (CRC), oxaliplatin-induced neuropathy has emerged as a prominent dose-limiting side effect associated with quality of life decrements. Ongoing monitoring and management of neuropathy is important for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaiser, Karen, Lyleroehr, Madison, Shaunfield, Sara, Lacson, Leilani, Corona, Maria, Kircher, Sheetal, Nittve, Malin, Cella, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031152/ https://www.ncbi.nlm.nih.gov/pubmed/32104551 http://dx.doi.org/10.4251/wjgo.v12.i2.205

Ejemplares similares

Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre
por: Garcia, Sofia F, et al.
Publicado: (2022)

Oxaliplatin-induced neuropathy and colo-rectal cancer patient’s quality of life: Practical lessons from a prospective cross-sectional, real-world study
por: Prutianu, Iulian, et al.
Publicado: (2022)

How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?
por: Peipert, John Devin, et al.
Publicado: (2022)

Correction to: How do patients interpret and respond to a single‑item global indicator of cancer treatment tolerability?
por: Peipert, John Devin, et al.
Publicado: (2023)

The Combination of Zinc and Melatonin Enhanced Neuroprotection and Attenuated Neuropathy in Oxaliplatin-Induced Neurotoxicity
por: Ali, Mayyadah, et al.
Publicado: (2022)

Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity
por: Sałat, Kinga
Publicado: (2020)

Oxaliplatin-Induced Neuropathy in Colorectal Cancer
por: Weickhardt, Andrew, et al.
Publicado: (2011)

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy
por: Kono, Toru, et al.
Publicado: (2013)

Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN)
por: Argyriou, Andreas A.
Publicado: (2015)

Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity
por: Velasco, Roser, et al.
Publicado: (2021)

Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer
por: Kono, Toru, et al.
Publicado: (2011)

Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies
por: Cheng, Fang, et al.
Publicado: (2023)

A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
por: Kim, Su-Hyun, et al.
Publicado: (2018)

Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
por: Baek, Kyung Kee, et al.
Publicado: (2010)

Delayed Oxaliplatin-Related Severe Neurotoxicity in Metastatic Colorectal Cancer: A Case Report
por: Iimura, Yohei, et al.
Publicado: (2023)

Management of oxaliplatin-induced peripheral neuropathy
por: Saif, M Wasif, et al.
Publicado: (2005)

Long-term administration and efficacy of oxaliplatin with no neurotoxicity in a patient with rectal cancer: Association between neurotoxicity and the GSTP1 polymorphism
por: KITADE, HIRONORI, et al.
Publicado: (2014)

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Self-Management of Oxaliplatin-Related Peripheral Neuropathy in Colorectal Cancer Survivors
por: Tofthagen, Cindy, et al.
Publicado: (2013)

Efficacy of Goshajinkigan for Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients
por: Yoshida, Naohisa, et al.
Publicado: (2013)

Oxaliplatin neurotoxicity – no general ion channel surface-charge effect
por: Broomand, Amir, et al.
Publicado: (2009)

The Use of Calcium and Magnesium to Prevent Neurotoxicity in Patients Receiving Oxaliplatin
por: Martyn, Karon, et al.
Publicado: (2015)

Memantine ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection
por: Wang, Youyu, et al.
Publicado: (2022)

A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice
por: Calls, Aina, et al.
Publicado: (2022)

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer
por: Leonard, Gregory D, et al.
Publicado: (2005)

Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy
por: Cavaletti, Guido, et al.
Publicado: (2020)

Platinum accumulation in oxaliplatin‐induced peripheral neuropathy
por: Wei, Guoli, et al.
Publicado: (2021)

Validity and reliability of the Polish version of the Michigan Neuropathy Screening Instrument
por: Sutkowska, Edyta, et al.
Publicado: (2023)

Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer
por: Zhang, Xinjie, et al.
Publicado: (2020)

Dose Effects of Oxaliplatin on Persistent and Transient Na(+) Conductances and the Development of Neurotoxicity
por: Park, Susanna B., et al.
Publicado: (2011)

Efficacy of Exercise Rehabilitation Program in Relieving Oxaliplatin Induced Peripheral Neurotoxicity
por: Gui, Qi, et al.
Publicado: (2021)

Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity
por: Nepal, Mahesh R., et al.
Publicado: (2022)

A review of movement disorders in chemotherapy-induced neurotoxicity
por: Wang, Allison B., et al.
Publicado: (2021)

Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
por: Nagano, Katsumasa, et al.
Publicado: (2023)

Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index‐10 (FHNSI‐10)
por: Shaunfield, Sara, et al.
Publicado: (2021)

Small extracellular vesicles ameliorate peripheral neuropathy and enhance chemotherapy of oxaliplatin on ovarian cancer
por: Zhang, Yi, et al.
Publicado: (2021)

Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention
por: Oneda, Ester, et al.
Publicado: (2021)

Psychosocial adaptation and influencing factors among patients with chemotherapy-induced peripheral neuropathy
por: Zhou, Xiao, et al.
Publicado: (2022)

Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy
por: Yoshida, Yoichiro, et al.
Publicado: (2015)

Astragali radix: could it be an adjuvant for oxaliplatin-induced neuropathy?
por: Di Cesare Mannelli, Lorenzo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_efmnou8nm8c4moood7f4766fu8